Amgen Drops Drug Delivery Partnership, Targets Crohn’s Disease with TScan Pact

[{"selector":"#anim-1b0b4d41-6b3c-4f76-876d-327489d5ab1c","keyframes":{"opacity":[0,1]},"delay":0,"duration":1200,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-4c0d02c7-5c66-44b0-9918-4457ba840207","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

1. Amgen and Entera Bio end their drug delivery partnership.

[{"selector":"#anim-03f74ac1-fd68-46dd-85ae-b823b400082a","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

2. Amgen invested around $1.2 million in Entera's platform.

[{"selector":"#anim-68ca3af0-a912-43cf-83ad-f990bbdcabcd","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

3. Entera retains the rights to its technology.

[{"selector":"#anim-b19401af-fb8d-42e7-8310-c6284ba177d2","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

4. Amgen partners with TScan Therapeutics to identify novel targets in Crohn's disease.

[{"selector":"#anim-05c111f6-b6cd-4502-a06a-aa4427f28455","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

5. The partnership costs $30 million upfront.

[{"selector":"#anim-0fd5517c-4be4-4a4b-ad58-9eb2f09956db","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

6. TScan's technology identifies natural targets of T cell receptors.

[{"selector":"#anim-64f0cb88-1d68-4378-a758-798ece924d7b","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

7. Amgen plans to develop novel anti-inflammatory medicines.

[{"selector":"#anim-9e73cf35-566c-4ee0-bdb6-f58af67ec21b","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

8. TScan is entitled to royalties out of any product that the agreement may yield.

[{"selector":"#anim-58df3d60-da4e-4303-8c5b-e2666f02a038","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

9. Amgen made recent acquisitions of Horizon Therapeutics and ChemoCentryx.

[{"selector":"#anim-4495ac79-ec34-4d5f-b658-cfda997d0696","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

10. Amgen also signed a $2 billion agreement with Synaffix.

[{"selector":"#anim-2da1206b-f7b0-450a-a531-2a32eb75b12c","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

Swipe up for more BIOMARKER news!

[{"selector":"#anim-fd184cb1-5ef5-4042-ac0c-125c0dae01e5","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Learn more